|
 |
| | | | | Investments | | | | | | | | €30 million for a secure future | | |  | | | Merckle Biotec invested €30 million in a highly efficient multipurpose plant to manufacture biotech active ingredients from cell cultures. Construction started in 2004 and qualification of the facility began in 2005 once equipment and machinery have been installed.
The company invested an additional €10 million in the modernization of an existing plant in Blaubeuren-Weiler to produce prefilled syringes. Start-up at this site could also be accomplished in 2005. | | | These investments have made it possible to place the entire value-added chain for manufacturing biopharmaceuticals in the hands of a single company. This approach is enhanced by streamlined procedures and a clear focus of responsibility.
The manufacturing license of Merckle Biotec according to the German pharmaceuticals law comprises all relevant activities in the development and manufacturing of biopharmaceuticals and underlines the high quality level of the company and its employees. In addition, mock inspections by external consultants ensure the compliance with special US - FDA requirements.
| | | | | | | | |
|
|
|
Links